Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 25 to 36 of 93 entries
Sorted by: Best Match Show Resources per page
How much of a general practitioner's prescribing is outside his/her control?.

Irish medical journal

Kelly A, Quinn R.
PMID: 9973752
Ir Med J. 1998 Oct-Nov;91(5):168-72.

OBJECTIVE: To analyse and quantify that portion of one General Practioner's prescribing that is outside his/her control.DESIGN: Detailed analysis of one General Practioner's General Medical Services prescribing over a three month period during 1996.SETTING: A Group Practice in Sligo,...

Cite
Kelly A, Quinn R. How much of a general practitioner's prescribing is outside his/her control?. Ir Med J. 1998;91(5):168-72
Kelly, A., & Quinn, R. (1998). How much of a general practitioner's prescribing is outside his/her control?. Irish medical journal, 91(5), 168-72.
Kelly, A, and Quinn, R. "How much of a general practitioner's prescribing is outside his/her control?." Irish medical journal vol. 91,5 (1998): 168-72.
Kelly A, Quinn R. How much of a general practitioner's prescribing is outside his/her control?. Ir Med J. 1998 Oct-Nov;91(5):168-72. PMID: 9973752.
Copy Download .nbib Format: NLM
India to modify drug policy.

Lancet (London, England)

Mangla B.
PMID: 8102733
Lancet. 1993 Sep 04;342(8871):608. doi: 10.1016/0140-6736(93)91424-k.

No abstract available.

Cite
Mangla B. India to modify drug policy. Lancet. 1993;342(8871):608doi: 10.1016/0140-6736(93)91424-k.
Mangla, B. (1993). India to modify drug policy. Lancet (London, England), 342(8871), 608. https://doi.org/10.1016/0140-6736(93)91424-k
Mangla, B. "India to modify drug policy." Lancet (London, England) vol. 342,8871 (1993): 608. doi: https://doi.org/10.1016/0140-6736(93)91424-k
Mangla B. India to modify drug policy. Lancet. 1993 Sep 04;342(8871):608. doi: 10.1016/0140-6736(93)91424-k. PMID: 8102733.
Copy Download .nbib Format: NLM
Curbing drug bills.

Lancet (London, England)

Kimbel KH.
PMID: 8094207
Lancet. 1993 Feb 13;341(8842):441. doi: 10.1016/0140-6736(93)93039-4.

No abstract available.

Cite
Kimbel KH. Curbing drug bills. Lancet. 1993;341(8842):441doi: 10.1016/0140-6736(93)93039-4.
Kimbel, K. H. (1993). Curbing drug bills. Lancet (London, England), 341(8842), 441. https://doi.org/10.1016/0140-6736(93)93039-4
Kimbel, K H. "Curbing drug bills." Lancet (London, England) vol. 341,8842 (1993): 441. doi: https://doi.org/10.1016/0140-6736(93)93039-4
Kimbel KH. Curbing drug bills. Lancet. 1993 Feb 13;341(8842):441. doi: 10.1016/0140-6736(93)93039-4. PMID: 8094207.
Copy Download .nbib Format: NLM
Why and how to monitor the cost and evaluate the cost-effectiveness of HIV services in countries.

AIDS (London, England)

Beck EJ, Santas XM, Delay PR.
PMID: 18664958
AIDS. 2008 Jul;22:S75-85. doi: 10.1097/01.aids.0000327626.77597.fa.

The number of people in the world living with HIV is increasing as HIV-related mortality has declined but the annual number of people newly infected with HIV has not. The international response to contain the HIV pandemic, meanwhile, has...

Cite
Beck EJ, Santas XM, Delay PR. Why and how to monitor the cost and evaluate the cost-effectiveness of HIV services in countries. AIDS. 2008;22:S75-85doi: 10.1097/01.aids.0000327626.77597.fa.
Beck, E. J., Santas, X. M., & Delay, P. R. (2008). Why and how to monitor the cost and evaluate the cost-effectiveness of HIV services in countries. AIDS (London, England), 22S75-85. https://doi.org/10.1097/01.aids.0000327626.77597.fa
Beck, Eduard J, et al. "Why and how to monitor the cost and evaluate the cost-effectiveness of HIV services in countries." AIDS (London, England) vol. 22 (2008): S75-85. doi: https://doi.org/10.1097/01.aids.0000327626.77597.fa
Beck EJ, Santas XM, Delay PR. Why and how to monitor the cost and evaluate the cost-effectiveness of HIV services in countries. AIDS. 2008 Jul;22:S75-85. doi: 10.1097/01.aids.0000327626.77597.fa. PMID: 18664958.
Copy Download .nbib Format: NLM
Branded Price Variation in the United States Drug Market, 2010 to 2019.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research

Levy J, Ippolito B.
PMID: 34452701
Value Health. 2021 Sep;24(9):1237-1240. doi: 10.1016/j.jval.2021.04.1272. Epub 2021 Aug 05.

The transaction price for branded drugs in the United States often varies widely by the eventual payer, a fact that can complicate research and policy discussions surrounding drug pricing. We combine publicly-available data on branded drug prices from a...

Cite
Levy J, Ippolito B. Branded Price Variation in the United States Drug Market, 2010 to 2019. Value Health. 2021;24(9):1237-1240doi: 10.1016/j.jval.2021.04.1272.
Levy, J., & Ippolito, B. (2021). Branded Price Variation in the United States Drug Market, 2010 to 2019. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 24(9), 1237-1240. https://doi.org/10.1016/j.jval.2021.04.1272
Levy, Joseph, and Ippolito, Benedic. "Branded Price Variation in the United States Drug Market, 2010 to 2019." Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research vol. 24,9 (2021): 1237-1240. doi: https://doi.org/10.1016/j.jval.2021.04.1272
Levy J, Ippolito B. Branded Price Variation in the United States Drug Market, 2010 to 2019. Value Health. 2021 Sep;24(9):1237-1240. doi: 10.1016/j.jval.2021.04.1272. Epub 2021 Aug 05. PMID: 34452701.
Copy Download .nbib Format: NLM
The effects of pricing policy on the prices and supply of low-cost medicines in Shandong, China: evidence from an interrupted time series analysis.

BMC public health

Rong X, Yin J, Duan S, Sun Q, Babar ZU.
PMID: 32349722
BMC Public Health. 2020 Apr 29;20(1):588. doi: 10.1186/s12889-020-08746-x.

BACKGROUND: In China, some medicines had a supply problem. In 2015, to address this problem, the Chinese government issued a policy to raise the price cap for some shorted low-cost medicines (LCMs). The objective was to assess the effects...

Cite
Rong X, Yin J, Duan S, et al. The effects of pricing policy on the prices and supply of low-cost medicines in Shandong, China: evidence from an interrupted time series analysis. BMC Public Health. 2020;20(1):588doi: 10.1186/s12889-020-08746-x.
Rong, X., Yin, J., Duan, S., Sun, Q., & Babar, Z. U. (2020). The effects of pricing policy on the prices and supply of low-cost medicines in Shandong, China: evidence from an interrupted time series analysis. BMC public health, 20(1), 588. https://doi.org/10.1186/s12889-020-08746-x
Rong, Xuejing, et al. "The effects of pricing policy on the prices and supply of low-cost medicines in Shandong, China: evidence from an interrupted time series analysis." BMC public health vol. 20,1 (2020): 588. doi: https://doi.org/10.1186/s12889-020-08746-x
Rong X, Yin J, Duan S, Sun Q, Babar ZU. The effects of pricing policy on the prices and supply of low-cost medicines in Shandong, China: evidence from an interrupted time series analysis. BMC Public Health. 2020 Apr 29;20(1):588. doi: 10.1186/s12889-020-08746-x. PMID: 32349722; PMCID: PMC7191794.
Copy Download .nbib Format: NLM
Impacts of the zero mark-up drug policy on hospitalization expenses of COPD inpatients in Sichuan province, western China: an interrupted time series analysis.

BMC health services research

Wang J, Li P, Wen J.
PMID: 32513170
BMC Health Serv Res. 2020 Jun 08;20(1):519. doi: 10.1186/s12913-020-05378-0.

BACKGROUND: Since 1950, the hospitals had been permitted to take a 15% mark-up of drug purchase price to remedy the loss of public hospitals and doctors' salaries in China due to tight government budget. This policy resulted in an...

Cite
Wang J, Li P, Wen J. Impacts of the zero mark-up drug policy on hospitalization expenses of COPD inpatients in Sichuan province, western China: an interrupted time series analysis. BMC Health Serv Res. 2020;20(1):519doi: 10.1186/s12913-020-05378-0.
Wang, J., Li, P., & Wen, J. (2020). Impacts of the zero mark-up drug policy on hospitalization expenses of COPD inpatients in Sichuan province, western China: an interrupted time series analysis. BMC health services research, 20(1), 519. https://doi.org/10.1186/s12913-020-05378-0
Wang, Junman, et al. "Impacts of the zero mark-up drug policy on hospitalization expenses of COPD inpatients in Sichuan province, western China: an interrupted time series analysis." BMC health services research vol. 20,1 (2020): 519. doi: https://doi.org/10.1186/s12913-020-05378-0
Wang J, Li P, Wen J. Impacts of the zero mark-up drug policy on hospitalization expenses of COPD inpatients in Sichuan province, western China: an interrupted time series analysis. BMC Health Serv Res. 2020 Jun 08;20(1):519. doi: 10.1186/s12913-020-05378-0. PMID: 32513170; PMCID: PMC7282107.
Copy Download .nbib Format: NLM
International reference pricing for prescription drugs: a landscape analysis.

Journal of managed care & specialty pharmacy

Rand LZ, Kesselheim AS.
PMID: 34464208
J Manag Care Spec Pharm. 2021 Sep;27(9):1309-1313. doi: 10.18553/jmcp.2021.27.9.1309.

During the Trump administration, members of Congress and the administration proposed the introduction of international reference pricing (IRP) to Medicare in order to reduce US drug spending by benchmarking prices to those in other countries. Many other countries currently...

Cite
Rand LZ, Kesselheim AS. International reference pricing for prescription drugs: a landscape analysis. J Manag Care Spec Pharm. 2021;27(9):1309-1313doi: 10.18553/jmcp.2021.27.9.1309.
Rand, L. Z., & Kesselheim, A. S. (2021). International reference pricing for prescription drugs: a landscape analysis. Journal of managed care & specialty pharmacy, 27(9), 1309-1313. https://doi.org/10.18553/jmcp.2021.27.9.1309
Rand, Leah Z, and Kesselheim, Aaron S. "International reference pricing for prescription drugs: a landscape analysis." Journal of managed care & specialty pharmacy vol. 27,9 (2021): 1309-1313. doi: https://doi.org/10.18553/jmcp.2021.27.9.1309
Rand LZ, Kesselheim AS. International reference pricing for prescription drugs: a landscape analysis. J Manag Care Spec Pharm. 2021 Sep;27(9):1309-1313. doi: 10.18553/jmcp.2021.27.9.1309. PMID: 34464208.
Copy Download .nbib Format: NLM
Drug Pricing and Oncology: What's Really Driving Costs?.

JCO oncology practice

Jung A.
PMID: 32396792
JCO Oncol Pract. 2020 May;16(5):270-272. doi: 10.1200/OP.20.00212.

No abstract available.

Cite
Jung A. Drug Pricing and Oncology: What's Really Driving Costs?. JCO Oncol Pract. 2020;16(5):270-272doi: 10.1200/OP.20.00212.
Jung, A. (2020). Drug Pricing and Oncology: What's Really Driving Costs?. JCO oncology practice, 16(5), 270-272. https://doi.org/10.1200/OP.20.00212
Jung, Alex. "Drug Pricing and Oncology: What's Really Driving Costs?." JCO oncology practice vol. 16,5 (2020): 270-272. doi: https://doi.org/10.1200/OP.20.00212
Jung A. Drug Pricing and Oncology: What's Really Driving Costs?. JCO Oncol Pract. 2020 May;16(5):270-272. doi: 10.1200/OP.20.00212. PMID: 32396792.
Copy Download .nbib Format: NLM
Continuity and change in the drug supply chain: actors, actions, and aversions.

Journal of medical economics

Mendoza RL.
PMID: 33941029
J Med Econ. 2021 Jan-Dec;24(1):689-697. doi: 10.1080/13696998.2021.1925123.

AIM: The pharmaceutical or drug supply chain is the means through which prescription medicines are manufactured, stocked, and delivered to consumers. How the complexity and fragmentation of this supply chain shape or reshape the decisions and courses of action...

Cite
Mendoza RL. Continuity and change in the drug supply chain: actors, actions, and aversions. J Med Econ. 2021;24(1):689-697doi: 10.1080/13696998.2021.1925123.
Mendoza, R. L. (2021). Continuity and change in the drug supply chain: actors, actions, and aversions. Journal of medical economics, 24(1), 689-697. https://doi.org/10.1080/13696998.2021.1925123
Mendoza, Roger Lee. "Continuity and change in the drug supply chain: actors, actions, and aversions." Journal of medical economics vol. 24,1 (2021): 689-697. doi: https://doi.org/10.1080/13696998.2021.1925123
Mendoza RL. Continuity and change in the drug supply chain: actors, actions, and aversions. J Med Econ. 2021 Jan-Dec;24(1):689-697. doi: 10.1080/13696998.2021.1925123. PMID: 33941029.
Copy Download .nbib Format: NLM
Current Situation, Determinants, and Solutions to Drug Shortages in Shaanxi Province, China: A Qualitative Study.

PloS one

Yang C, Wu L, Cai W, Zhu W, Shen Q, Li Z, Fang Y.
PMID: 27780218
PLoS One. 2016 Oct 25;11(10):e0165183. doi: 10.1371/journal.pone.0165183. eCollection 2016.

OBJECTIVE: Drug shortages were a complex global problem. The aim of this study was to analyze, characterize, and assess the drug shortages, and identify possible solutions in Shaanxi Province, western China.METHODS: A qualitative methodological approach was conducted during May-June...

Cite
Yang C, Wu L, Cai W, et al. Current Situation, Determinants, and Solutions to Drug Shortages in Shaanxi Province, China: A Qualitative Study. PLoS One. 2016;11(10):e0165183doi: 10.1371/journal.pone.0165183.
Yang, C., Wu, L., Cai, W., Zhu, W., Shen, Q., Li, Z., & Fang, Y. (2016). Current Situation, Determinants, and Solutions to Drug Shortages in Shaanxi Province, China: A Qualitative Study. PloS one, 11(10), e0165183. https://doi.org/10.1371/journal.pone.0165183
Yang, Caijun, et al. "Current Situation, Determinants, and Solutions to Drug Shortages in Shaanxi Province, China: A Qualitative Study." PloS one vol. 11,10 (2016): e0165183. doi: https://doi.org/10.1371/journal.pone.0165183
Yang C, Wu L, Cai W, Zhu W, Shen Q, Li Z, Fang Y. Current Situation, Determinants, and Solutions to Drug Shortages in Shaanxi Province, China: A Qualitative Study. PLoS One. 2016 Oct 25;11(10):e0165183. doi: 10.1371/journal.pone.0165183. eCollection 2016. PMID: 27780218; PMCID: PMC5079602.
Copy Download .nbib Format: NLM
How to save big on Rx.

Consumer reports

[No authors listed]
PMID: 25423686
Consum Rep. 2014 Dec;79(12):20.

No abstract available.

Cite
How to save big on Rx. Consum Rep. 2014;79(12):20
(2014). How to save big on Rx. Consumer reports, 79(12), 20.
"How to save big on Rx." Consumer reports vol. 79,12 (2014): 20.
How to save big on Rx. Consum Rep. 2014 Dec;79(12):20. PMID: 25423686.
Copy Download .nbib Format: NLM
Showing 25 to 36 of 93 entries